Olodaterol Case Study
In four pivotal, 48-week, phase III trials, the addition of olodaterol 5 µg once daily to usual maintenance therapy significantly (p<0.0005).44
Cost Effectiveness
According to US estimates, the average wholesale price of Striverdi® Respimat is around $87.19 while that of Spiriva® Handihaler is $357.37.9,11 Olodaterol appears to be more expensive than similar drugs of its class such as indacaterol which has an AWP of $8.08.45 However, no head-to-head trials comparing olodaterol to indacaterol have yet been published to prove if olodaterol therapy translates into better clinical outcomes on the expense of increased cost. Furthermore, no cost-estimates or cost-effectiveness analyses have yet been done on the combination of Tiotropium/Olodaterol …show more content…
Tiotropium managed to improve lung function, exercise endurance and HRQOL in addition to its ability to reduce exacerbations compared to the LABAs salmeterol, formoterol and indacaterol.9 Similarly, Olodaterol demonstrated symptomatic improvements in lung function over 24-hrs and enhanced health outcomes, as assessed by the SGRQ compared to tiotropium, salmeterol and formoterol.11 The fixed dose-combination of Tiotropium 5 μg + Olodaterol 5 μg delivered via the Respimat® Soft Mist™ inhaler, evaluated in several Phase III trials, has demonstrated sustained improvements in lung function, as measured by trough forced expiratory volume in one second (FEV1) and in St. George’s Respiratory Questionnaire (SGRQ) total score over 6 to 48 weeks compared to those receiving olodaterol or tiotropium alone.46 The FDC has an acceptable safety profile with most frequent adverse effects being dry mouth, nasopharyngitis, upper respiratory tract infection, bronchitis, and cough. Tiotropium+ Olodaterol is not indicated to treat acute deteriorations of COPD or to treat asthma. This LAMA/LABA combination if approved would be the first of its kind on the
Cost Effectiveness
According to US estimates, the average wholesale price of Striverdi® Respimat is around $87.19 while that of Spiriva® Handihaler is $357.37.9,11 Olodaterol appears to be more expensive than similar drugs of its class such as indacaterol which has an AWP of $8.08.45 However, no head-to-head trials comparing olodaterol to indacaterol have yet been published to prove if olodaterol therapy translates into better clinical outcomes on the expense of increased cost. Furthermore, no cost-estimates or cost-effectiveness analyses have yet been done on the combination of Tiotropium/Olodaterol …show more content…
Tiotropium managed to improve lung function, exercise endurance and HRQOL in addition to its ability to reduce exacerbations compared to the LABAs salmeterol, formoterol and indacaterol.9 Similarly, Olodaterol demonstrated symptomatic improvements in lung function over 24-hrs and enhanced health outcomes, as assessed by the SGRQ compared to tiotropium, salmeterol and formoterol.11 The fixed dose-combination of Tiotropium 5 μg + Olodaterol 5 μg delivered via the Respimat® Soft Mist™ inhaler, evaluated in several Phase III trials, has demonstrated sustained improvements in lung function, as measured by trough forced expiratory volume in one second (FEV1) and in St. George’s Respiratory Questionnaire (SGRQ) total score over 6 to 48 weeks compared to those receiving olodaterol or tiotropium alone.46 The FDC has an acceptable safety profile with most frequent adverse effects being dry mouth, nasopharyngitis, upper respiratory tract infection, bronchitis, and cough. Tiotropium+ Olodaterol is not indicated to treat acute deteriorations of COPD or to treat asthma. This LAMA/LABA combination if approved would be the first of its kind on the